Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAQW9M)

Drug Name
SFX-01 Drug Info
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Subarachnoid hemorrhage 8B01 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMAQW9M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Nuclear factor erythroid 2-related factor 2 (Nrf2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Omaveloxolone DMLMNFX Friedreich's ataxia 8A03.10 Approved [4]
CXA10 DMM7Z6K Focal segmental glomerulosclerosis MF8Y Phase 2 [5]
ABT-RTA-408 DM9Y1XB Non-small-cell lung cancer 2C25.Y Phase 2 [6]
OT-551 DMTNOXQ Ocular inflammation 9C61.24 Phase 2 [7]
OT551 DMHKIOF Age-related macular degeneration 9B75.0 Phase 2 [8]
HPP971 DMZXG7Q Non-alcoholic steatohepatitis DB92.1 Phase 1 [9]
PMID28454500-Compound-57 DMTK9M6 N. A. N. A. Patented [10]
PMID28454500-Compound-8 DM6BQFA N. A. N. A. Patented [10]
Pyrazino[2,1-a]isoquinolin derivative 4 DMKTNBC N. A. N. A. Patented [10]
PMID28454500-Compound-36 DM5RZWG N. A. N. A. Patented [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nuclear factor erythroid 2-related factor 2 (Nrf2) TTA6ZN2 NF2L2_HUMAN Activator [3]

References

1 ClinicalTrials.gov (NCT02970682) SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer (STEM). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02614742) SFX-01 After Subarachnoid Haemorrhage (SAS). U.S. National Institutes of Health.
3 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
6 National Cancer Institute Drug Dictionary (drug id 756624).
7 New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
8 Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325.
9 Clinical pipeline report, company report or official report of vTv Therapeutics.
10 Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.